Background/Aim: In clinical research setting, accurate and precise measurement of glomerular filtration rate (GFR) is essential to overcome the limitations of GFR estimation with equations, which are often unreliable. In recent decades, a method for measuring GFR by plasma clearance of iohexol, a non-ionic radiocontrast agent, was developed. To evaluate the safety of the procedure, we aimed to review all immediate adverse reactions that could be related to iohexol administration in our group’s 25 years worth of experience. Methods: We retrospectively reviewed all GFR investigations in 2,891 patients, between 1992 and 2016, as part of 37 clinical trials coordinated by our group. Subjects with disparate renal diseases, kidney transplant recipients, and living donors – all with different renal function categories – were included in the surveyed clinical trials. Results: During 15,147 GFR measurements, only one treatment-related event of moderate intensity was identified. Flushing, urticaria, and itching were observed in a diabetic patient a few minutes after iohexol administration during the first GFR measurement. The event recovered without sequelae after intravenous injection of methylprednisolone sodium succinate. The patient was not hospitalized and the event was categorized as non-serious. Eight additional non-serious events observed closely following iohexol injection were considered as not related to treatment. Thus, independent of disease conditions and GFR categories, the overall rate of treatment-related events was 0.0066%. Conclusion: Iohexol administration for GFR measurement is a safe procedure, even in repeated investigations in the same subject, that should be adopted in clinical research and, when needed, also in clinical practice.

Vart P, Grams ME: Measuring and assessing kidney function. Semin Nephrol 2016; 36: 262–272.
Gaspari F, Ruggenenti P, Porrini E, Motterlini N, Cannata A, Carrara F, Jimenez Sosa A, Cella C, Ferrari S, Stucchi N, Parvanova A, Iliev I, Trevisan R, Bossi A, Zaletel J, Remuzzi G: The GFR and GFR decline cannot be accurately estimated in type 2 diabetics. Kidney Int 2013; 84: 164–173.
Ruggenenti P, Gaspari F, Cannata A, Carrara F, Cella C, Ferrari S, Stucchi N, Prandini S, Ene-Iordache B, Diadei O, Perico N, Ondei P, Pisani A, Buongiorno E, Messa P, Dugo M, Remuzzi G: Measuring and estimating GFR and treatment effect in ADPKD patients: results and implications of a longitudinal cohort study. PLoS One 2012; 7: e32533.
Gaspari F, Ferrari S, Stucchi N, Centemeri E, Carrara F, Pellegrino M, Gherardi G, Gotti E, Segoloni G, Salvadori M, Rigotti P, Valente U, Donati D, Sandrini S, Sparacino V, Remuzzi G, Perico N: Performance of different prediction equations for estimating renal function in kidney transplantation. Am J Transplant 2004; 4: 1826–1835.
Soveri I, Berg UB, Bjork J, Elinder CG, Grubb A, Mejare I, Sterner G, Back SE: Measuring GFR: a systematic review. Am J Kidney Dis 2014; 64: 411–424.
Brown SC, O’Reilly PH: Iohexol clearance for the determination of glomerular filtration rate in clinical practice: evidence for a new gold standard. J Urol 1991; 146: 675–679.
Gaspari F, Perico N, Ruggenenti P, Mosconi L, Amuchastegui CS, Guerini E, Daina E, Remuzzi G: Plasma clearance of nonradioactive iohexol as a measure of glomerular filtration rate. J Am Soc Nephrol 1995; 6: 257–263.
Delanaye P, Ebert N, Melsom T, Gaspari F, Mariat C, Cavalier E, Bjork J, Christensson A, Nyman U, Porrini E, Remuzzi G, Ruggenenti P, Schaeffner E, Soveri I, Sterner G, Eriksen BO, Back SE: Iohexol plasma clearance for measuring glomerular filtration rate in clinical practice and research: a review. Part 1: how to measure glomerular filtration rate with iohexol? Clin Kidney J 2016; 9: 682–699.
Delanaye P, Melsom T, Ebert N, Back SE, Mariat C, Cavalier E, Bjork J, Christensson A, Nyman U, Porrini E, Remuzzi G, Ruggenenti P, Schaeffner E, Soveri I, Sterner G, Eriksen BO, Gaspari F: Iohexol plasma clearance for measuring glomerular filtration rate in clinical practice and research: a review. Part 2: why to measure glomerular filtration rate with iohexol? Clin Kidney J 2016; 9: 700–704.
Gaspari F, Perico N, Matalone M, Signorini O, Azzollini N, Mister M, Remuzzi G: Precision of plasma clearance of iohexol for estimation of GFR in patients with renal disease. J Am Soc Nephrol 1998; 9: 310–313.
Andrew E, Dahlstrom K, Sveen K, Hvinden G, Holager T, Mowinckel P, Renaa T, Laulund S: Intravascular studies with iohexol (Omnipaque). Results from the first 49 clinical trials. Eur J Radiol 1985; 5: 68–76.
Katayama H, Yamaguchi K, Kozuka T, Takashima T, Seez P, Matsuura K: Adverse reactions to ionic and nonionic contrast media. A report from the Japanese Committee on the Safety of Contrast Media. Radiology 1990; 175: 621–628.
Pedersen SH, Svaland MG, Reiss AL, Andrew E: Late allergy-like reactions following vascular administration of radiography contrast media. Acta Radiol 1998; 39: 344–348.
O’Reilly PH, Brooman PJ, Martin PJ, Pollard AJ, Farah NB, Mason GC: Accuracy and reproducibility of a new contrast clearance method for the determination of glomerular filtration rate. Br Med J (Clin Res Ed) 1986; 293: 234–236.
Nilsson-Ehle P: Iohexol Clearance for the Determination of Glomerular Filtration Rate: 15 years’ Experience in Clinical Practice. http://www.Ifcc.Org/media/477078/ejifcc2001vol13no2pp048-052.Pdf. eJIFCC 2001; 13.
Summary of recommendation statements. Chapter 1: definition and classification of CKD. Kidney Int Suppl 2013; 3: 5–14.
Christiansen C: X-ray contrast media – an overview. Toxicology 2005; 209: 185–187.
Wolf GL, Arenson RL, Cross AP: A prospective trial of ionic vs nonionic contrast agents in routine clinical practice: comparison of adverse effects. AJR Am J Roentgenol 1989; 152: 939–944.
Cochran ST, Bomyea K, Sayre JW: Trends in adverse events after IV administration of contrast media. AJR Am J Roentgenol 2001; 176: 1385–1388.
Thomsen HS, Bush WH Jr: Adverse effects of contrast media: incidence, prevention and management. Drug Saf 1998; 19: 313–324.
Gomi T, Nagamoto M, Hasegawa M, Katoh A, Sugiyama M, Murata N, Kunihiro T, Kohda E: Are there any differences in acute adverse reactions among five low-osmolar non-ionic iodinated contrast media? Eur Radiol 2010; 20: 1631–1635.
Kim SR, Lee JH, Park KH, Park HJ, Park JW: Varied incidence of immediate adverse reactions to low-osmolar non-ionic iodide radiocontrast media used in computed tomography. Clin Exp Allergy 2017; 47: 106–112.
Lundqvist S, Holmberg G, Jakobsson G, Lithner F, Skinningsrud K, Stegmayr B, Hietala SO: Assessment of possible nephrotoxicity from iohexol in patients with normal and impaired renal function. Acta Radiol 1998; 39: 362–367.
Ansell G, Tweedie MC, West CR, Evans P, Couch L: The current status of reactions to intravenous contrast media. Invest Radiol 1980; 15(6 suppl):S32–S39.
Mita H, Tadokoro K, Akiyama K: Detection of IgE antibody to a radiocontrast medium. Allergy 1998; 53: 1133–1140.
Westhoff-Bleck M, Bleck JS, Jost S: The adverse effects of angiographic radiocontrast media. Drug Saf 1991; 6: 28–36.
Brockow K: Immediate and delayed cutaneous reactions to radiocontrast media. Chem Immunol Allergy 2012; 97: 180–190.
Seong JM, Choi NK, Lee J, Chang Y, Kim YJ, Yang BR, Jin XM, Kim JY, Park BJ: Comparison of the safety of seven iodinated contrast media. J Korean Med Sci 2013; 28: 1703–1710.
Bush WH, Swanson DP: Acute reactions to intravascular contrast media: types, risk factors, recognition, and specific treatment. AJR Am J Roentgenol 1991; 157: 1153–1161.
Heron CW, Underwood SR, Dawson P: Electrocardiographic changes during intravenous urography: a study with sodium iothalamate and iohexol. Clin Radiol 1984; 35: 137–141.
Aurell M: Accurate and feasible measurements of GFR – is the iohexol clearance the answer? Nephrol Dial Transplant 1994; 9: 1222–1224.
Nilsson-Ehle P, Grubb A: New markers for the determination of GFR: iohexol clearance and cystatin C serum concentration. Kidney Int Suppl 1994; 47:S17–S19.
Luis-Lima S, Gaspari F, Negrin-Mena N, Carrara F, Diaz-Martin L, Jimenez-Sosa A, Gonzalez-Rinne F, Torres A, Porrini E: Iohexol plasma clearance simplified by dried blood spot testing. Nephrol Dial Transplant 2017, Epub ahead of print.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.